NOAC Prescription Volume over Time
Notes: For the three NOAC drugs we study, figure shows the average number of prescribed beneficiaries per quarter, per physician, in our sample. The average covers all physician-quarters in our sample, including those with zero prescriptions. The FDA first approved Pradaxa in 2010, Xarelto in 2011, and Eliquis in 2012. Data are from a 40 percent of Medicare Part D claims.